These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 7687641

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team.
    Reichman RC, Morse GD, Demeter LM, Resnick L, Bassiakos Y, Fischl M, Para M, Powderly W, Leedom J, Greisberger C.
    J Infect Dis; 1995 Feb; 171(2):297-304. PubMed ID: 7531207
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors.
    Shafer RW, Winters MA, Iversen AK, Merigan TC.
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2887-90. PubMed ID: 9124861
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.
    Chong KT, Pagano PJ.
    Antiviral Res; 1997 Mar; 34(1):51-63. PubMed ID: 9107385
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro.
    Merrill DP, Moonis M, Chou TC, Hirsch MS.
    J Infect Dis; 1996 Feb; 173(2):355-64. PubMed ID: 8568296
    [Abstract] [Full Text] [Related]

  • 12. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
    Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC.
    J Virol; 1996 Feb; 70(2):1086-90. PubMed ID: 8551567
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.
    Palmer S, Harmenberg J, Cox S.
    Antimicrob Agents Chemother; 1996 May; 40(5):1285-8. PubMed ID: 8723486
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In-vitro selection of HIV-1 variants resistant to non-nucleoside reverse transcriptase inhibitors in monocyte-derived macrophages.
    Been-Tiktak AM, de Haas CJ, de Graaf L, Boucher CA, Verhoef J, Borleffs JC, Nottet HS, Schuurman R.
    J Antimicrob Chemother; 1997 Dec; 40(6):847-53. PubMed ID: 9462437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.